Markus Manns
Markus Manns is a portfolio manager at Union Investment, where he focuses on healthcare investments. He has commented on BioNTech's strategic developments in the oncology field, particularly regarding the promising bispecific antibody BNT327, which combines mechanisms to enhance cancer treatment efficacy. Manns has praised the collaboration between BioNTech and Bristol Myers Squibb as a significant move in cancer research.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| United Kingdom | 1 | 4.00 | 0.03% | +0% | 67,886,011 | 23,670 | $2,700,000 | 941$ |
| Totals | 1 | 67,886,011 | 23,670 | $2,700,000 | 941$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
United Kingdom:
Markus Manns described the cuts to Novo's growth outlook as 'a shocker'.
4
Switzerland:
Markus Manns is a portfolio manager at Union Investment who commented on the promising developments in cancer medicine.
8